ResultsIQ › Latest results › Mukka Proteins Limited
Mukka Proteins Limited Q2 FY27 results deck summary
NSE: MUKKA · BSE: 544135
Results deck of 10 Nov 2026, summarised by AI from the filing.
Management targets revenue of ₹3,000+ cr by FY30, more than 2x growth in ~4 years from ₹1,449 cr in FY26.
Key takeaways
- FY30 target Management targets revenue of ₹3,000+ cr by FY30, more than 2x growth in ~4 years from ₹1,449 cr in FY26.
- Oman start The new Al Juba facility in Oman commenced commercial production in Q2 FY27, adding fishmeal, fish oil and paste capacity.
- Margin dip EBITDA margin was 9.9% in Q2 FY27 against 10.7% in Q2 FY26.
Mukka Proteins Limited Q2 FY27 results
As filed: Revenue ₹509 cr (+108% year on year), EBITDA ₹42.3 cr (+101% year on year), PAT ₹17.7 cr (+153% year on year), EBITDA margin 8.3% (−26 bps).
The Q2 FY27 score, against the company's own trend, is for premium members.
Earlier results and the share price after them
- Q1 FY27: Revenue ₹490 cr (+186% year on year), EBITDA ₹48.0 cr (+243% year on year), PAT ₹18.6 cr (+300% year on year), EBITDA margin 9.8% (+161 bps). Score 85 of 100, Above trend. Revenue, EBITDA and profit growth were well above the company's own trend. EBITDA margin rose 161 bps year on year. Profit fell 13% from last quarter. Share price after the results: +33.0% in 30 days (Nifty 500: −3.4%).
- Q4 FY26: Revenue ₹381 cr (0% year on year), EBITDA ₹33.9 cr (+17% year on year), PAT ₹21.4 cr (+53% year on year), EBITDA margin 8.9% (+131 bps). Score 34 of 100, Below trend. Revenue and EBITDA growth were below the company's own trend; profit growth was in line with it. EBITDA margin rose 131 bps year on year. Other income 53% of PBT. Revenue fell 42% from last quarter. Share price after the results: −3.2% in 28 days (Nifty 500: +0.3%).
- Q3 FY26: Revenue ₹654 cr (+116% year on year), EBITDA ₹45.4 cr (+11% year on year), PAT ₹27.3 cr (+1% year on year), EBITDA margin 7.0% (−658 bps). Score 52 of 100, In line with trend. Revenue growth was well above the company's own trend; EBITDA and profit growth were below it. EBITDA margin fell 658 bps year on year. Share price after the results: −14.1% in 29 days (Nifty 500: −9.6%).
- Q2 FY26: Revenue ₹245 cr (+64% year on year), EBITDA ₹21.0 cr (+110% year on year), PAT ₹7.0 cr (+300% year on year), EBITDA margin 8.6% (+186 bps). Score 89 of 100, Above trend. EBITDA margin rose 186 bps year on year. Other income 60% of PBT. Not enough history for a trend yet: scored on growth alone. Share price after the results: −2.5% in 30 days (Nifty 500: −0.5%).
- Q1 FY26: Revenue ₹171 cr (−1% year on year), EBITDA ₹14.0 cr (0% year on year), PAT ₹2.0 cr (−60% year on year), EBITDA margin 8.2% (+9 bps). Score 11 of 100, Below trend. EBITDA margin was flat year on year. Other income 100% of PBT. Consolidated profit -60% but standalone +0%. Not enough history for a trend yet: scored on growth alone. Revenue fell 55% from last quarter. Share price after the results: −1.1% in 30 days (Nifty 500: +2.2%).
- Q4 FY25: Revenue ₹382 cr (+49% year on year), EBITDA ₹29.0 cr (−9% year on year), PAT ₹14.0 cr (−52% year on year), EBITDA margin 7.6% (−486 bps). Score 41 of 100, In line with trend. EBITDA margin fell 486 bps year on year. Not enough history for a trend yet: scored on growth alone. Profit fell 48% from last quarter. Share price after the results: −2.1% in 29 days (Nifty 500: +0.5%).
- Q3 FY25: Revenue ₹303 cr (−41% year on year), EBITDA ₹41.0 cr (+116% year on year), PAT ₹27.0 cr (+125% year on year), EBITDA margin 13.5% (+986 bps). Score 65 of 100, Above trend. EBITDA margin rose 986 bps year on year. Not enough history for a trend yet: scored on growth alone.
Past price moves after results do not indicate future moves. Not a recommendation.
Mukka Proteins Limited earnings call, investor presentation and press release summaries
- Q2 FY27: Results deck (10 Nov 2026)
- Q1 FY27: Results deck (13 Aug 2026)
- Q4 FY26: Results deck (22 May 2026)
- Q3 FY26: Results deck (13 Feb 2026)
Figures from the company's filings with NSE and BSE. Not investment advice.